Novel and Promising Strategies for Therapy of Post-Transplant Chronic GVHD

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2022 Sep 23

PMID 36145321

Authors

Irina Kostareva

Kirill Kirgizov

Elena Machneva

Nadezhda Ustyuzhanina

Nikolay Nifantiev

Yulia Skvortsova

Irina Shubina

Vera Reshetnikova

Timur Valiev

Svetlana Varfolomeeva

Mikhail Kiselevskiy

Affiliations

Soon will be listed here.

Abstract

Despite the achievements that have increased viability after the transplantation of allogeneic hematopoietic stem cells (aHSCT), chronic graft-versus-host disease (cGVHD) remains the main cause of late complications and post-transplant deaths. At the moment, therapy alternatives demonstrate limited effectiveness in steroid-refractory illness; in addition, we have no reliable data on the mechanism of this condition. The lack of drugs of choice for the treatment of GVHD underscores the significance of the design of new therapies. Improved understanding of the mechanism of chronic GVHD has secured new therapy goals, and organized diagnostic recommendations and the development of medical tests have ensured a general language and routes for studies in this field. These factors, combined with the rapid development of pharmacology, have helped speed up the search of medicines and medical studies regarding chronic GVHD. At present, we can hope for success in curing this formidable complication. This review summarizes the latest clinical developments in new treatments for chronic GVHD.

Citing Articles

Treatment of steroid-refractory graft versus host disease in children.

Gottardi F, Leardini D, Muratore E, Baccelli F, Cerasi S, Venturelli F Front Transplant. 2024; 2:1251112.

PMID: 38993897 PMC: 11235274. DOI: 10.3389/frtra.2023.1251112.

Identification of Fibroinflammatory and Fibrotic Transcriptomic Subsets of Human Cutaneous Sclerotic Chronic Graft-Versus-Host Disease.

Rosenstein R, Rose J, Brooks S, Tsai W, Gadina M, Pavletic S JID Innov. 2024; 4(2):100246.

PMID: 38357212 PMC: 10864809. DOI: 10.1016/j.xjidi.2023.100246.

Identification of single nucleotide polymorphisms (SNPs) associated with chronic graft-versus-host disease in patients undergoing allogeneic hematopoietic cell transplantation.

Mougeot J, Beckman M, Hovan A, Hasseus B, Legert K, Johansson J Support Care Cancer. 2023; 31(10):587.

PMID: 37731134 PMC: 10511391. DOI: 10.1007/s00520-023-08044-3.

References

Cumashi A, Ushakova N, Preobrazhenskaya M, DIncecco A, Piccoli A, Totani L . A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds. Glycobiology. 2007; 17(5):541-52. DOI: 10.1093/glycob/cwm014. View

Nygaard M, Wichert S, Berlin G, Toss F . Extracorporeal photopheresis for graft-vs-host disease: A literature review and treatment guidelines proposed by the Nordic ECP Quality Group. Eur J Haematol. 2020; 104(5):361-375. DOI: 10.1111/ejh.13381. View

Lorenz K, Rommel K, Mani J, Jin N, Hilgendorf I, Ho A . Modulation of lymphocyte subpopulations by extracorporeal photopheresis in patients with acute graft-versus-host disease or graft rejection. Leuk Lymphoma. 2014; 56(3):671-5. DOI: 10.3109/10428194.2014.931956. View

Brunstein C, Miller J, Cao Q, McKenna D, Hippen K, Curtsinger J . Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2010; 117(3):1061-70. PMC: 3035067. DOI: 10.1182/blood-2010-07-293795. View

Kim H, Koreth J, Whangbo J, Nikiforow S, Reynolds C, Stowe P . Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease. Blood Adv. 2022; 6(15):4392-4402. PMC: 9636330. DOI: 10.1182/bloodadvances.2022007773. View

Jacobsohn D, Chen A, Zahurak M, Piantadosi S, Anders V, Bolanos-Meade J . Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease. J Clin Oncol. 2007; 25(27):4255-61. DOI: 10.1200/JCO.2007.10.8456. View

Krylov V, Kaskova Z, Vinnitskiy D, Ustyuzhanina N, Grachev A, Chizhov A . Acid-promoted synthesis of per-O-sulfated fucooligosaccharides related to fucoidan fragments. Carbohydr Res. 2011; 346(5):540-50. DOI: 10.1016/j.carres.2011.01.005. View

Zhao K, Lin R, Fan Z, Chen X, Wang Y, Huang F . Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial. J Hematol Oncol. 2022; 15(1):22. PMC: 8900437. DOI: 10.1186/s13045-022-01240-4. View

Whangbo J, Kim H, Nikiforow S, Koreth J, Alho A, Falahee B . Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease. Blood Adv. 2019; 3(7):984-994. PMC: 6457229. DOI: 10.1182/bloodadvances.2018027474. View

10.

Jagasia M, Scheid C, Socie G, Ayuk F, Tischer J, Donato M . Randomized controlled study of ECP with methoxsalen as first-line treatment of patients with moderate to severe cGVHD. Blood Adv. 2019; 3(14):2218-2229. PMC: 6650730. DOI: 10.1182/bloodadvances.2019000145. View

11.

Sarantopoulos S, Cardones A, Sullivan K . How I treat refractory chronic graft-versus-host disease. Blood. 2019; 133(11):1191-1200. PMC: 6418480. DOI: 10.1182/blood-2018-04-785899. View

12.

Muroi K, Miyamura K, Okada M, Yamashita T, Murata M, Ishikawa T . Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study. Int J Hematol. 2015; 103(2):243-50. DOI: 10.1007/s12185-015-1915-9. View

13.

Drexler B, Buser A, Infanti L, Stehle G, Halter J, Holbro A . Extracorporeal Photopheresis in Graft-versus-Host Disease. Transfus Med Hemother. 2020; 47(3):214-225. PMC: 7315199. DOI: 10.1159/000508169. View

14.

Wang D, Liu Y, Lai X, Chen J, Cheng Q, Ma X . Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease. Front Immunol. 2021; 12:673636. PMC: 8278571. DOI: 10.3389/fimmu.2021.673636. View

15.

Matsuoka K . [Graft-versus-host disease: current understanding of immune pathogenesis and clinical treatment]. Rinsho Ketsueki. 2021; 62(8):1281-1287. DOI: 10.11406/rinketsu.62.1281. View

16.

Michallet M, Sobh M, Garban F, Bulabois C, Yakoub-Agha I, Coiteux V . Extracorporeal photopheresis for GVHD prophylaxis after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation: a prospective multicenter phase 2 study. Leuk Lymphoma. 2017; 59(2):372-380. DOI: 10.1080/10428194.2017.1334120. View

17.

Zanin-Zhorov A, Weiss J, Nyuydzefe M, Chen W, Scher J, Mo R . Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci U S A. 2014; 111(47):16814-9. PMC: 4250132. DOI: 10.1073/pnas.1414189111. View

18.

Zeiser R, Socie G . The development of ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. Blood Adv. 2020; 4(15):3789-3794. PMC: 7422131. DOI: 10.1182/bloodadvances.2020002097. View

19.

Uaprasert N, Tangcheewinsirikul N, Rojnuckarin P, Patell R, Zwicker J, Chiasakul T . Heparin-induced thrombocytopenia in patients with COVID-19: a systematic review and meta-analysis. Blood Adv. 2021; 5(21):4521-4534. PMC: 8455241. DOI: 10.1182/bloodadvances.2021005314. View

20.

Yalniz F, Murad M, Lee S, Pavletic S, Khera N, Shah N . Steroid Refractory Chronic Graft-Versus-Host Disease: Cost-Effectiveness Analysis. Biol Blood Marrow Transplant. 2018; 24(9):1920-1927. PMC: 8058632. DOI: 10.1016/j.bbmt.2018.03.008. View